|
Products |
| Products |
|
Diseases |  |
News |  |
| «12...1718192021222324252627...39313932» |
- | Keytruda (pembrolizumab) / Merck (MSD)
Trial completion date, Trial primary completion date, Surgery: Study of Combined Decompressive Spine Radiosurgery and Pembrolizumab (clinicaltrials.gov) - Sep 24, 2024
P1, N=10, Recruiting, Sponsor: Wake Forest University Health Sciences
Trial completion date: Sep 2024 --> Dec 2024 | Trial primary completion date: Sep 2024 --> Dec 2024
- | Ibrance (palbociclib) / Pfizer
Journal: Multispectral and molecular simulation of the interaction of human ?1-acid glycoprotein with palbociclib. (Pubmed Central) - Sep 23, 2024
And, molecular docking and dynamics simulations verified the experimental findings. Finally, most of the metal ions present in plasma, such as K+, Cu2+, Ca2+, Mg2+, Ni2+, Fe3+, and Co2+, are detrimental to the binding of palbociclib to HAG, with the exception of Zn2+, which is favorable.
- | Kisqali (ribociclib) / Novartis
Journal, Circulating tumor DNA: Acquired gene alterations in patients treated with ribociclib plus endocrine therapy or endocrine therapy alone using baseline and end-of-treatment circulating tumor DNA samples in the MONALEESA-2, -3, and -7 trials. (Pubmed Central) - Sep 23, 2024
This analysis identified acquired gene alterations in patients with HR+/HER2- advanced breast cancer treated with ribociclib plus ET or placebo plus ET. These data may support further studies on acquired resistance mechanisms and inform future systemic interventions in the post-CDK4/6 inhibitor setting.
- | Imfinzi (durvalumab) / AstraZeneca
Journal: Durvalumab with etoposide and carboplatin for patients with extensive-stage small cell lung cancer and interstitial lung disease: A multicenter, open-label prospective trial. (Pubmed Central) - Sep 23, 2024
These data may support further studies on acquired resistance mechanisms and inform future systemic interventions in the post-CDK4/6 inhibitor setting. Chemoimmunotherapy is a feasible treatment approach for patients with ES-SCLC and mild IIP.
- Inlyta (axitinib) / Pfizer, Keytruda (pembrolizumab) / Merck (MSD)
TARGETED FECAL MICROBIOTA TRANSPLANTATION IN PATIENTS RECEIVING PEMBROLIZUMAB PLUS AXITINIB FOR METASTATIC RENAL CELL CARCINOMA: PRELIMINARY RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (TACITO TRIAL) (A3) - Sep 23, 2024 - Abstract #UEGW2024UEGW_3669;
Chemoimmunotherapy is a feasible treatment approach for patients with ES-SCLC and mild IIP. Full abstract will be published on the day of presentation
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Journal, BRCA Biomarker, PD(L)-1 Biomarker, IO biomarker: Malignant pleural mesothelioma: The disdained member of thoracic oncology! (Pubmed Central) - Sep 23, 2024
This review article provides an overview of epidemiology, etiology, clinical manifestations, diagnostic approaches (including immunohistochemical and genetic markers), staging, and multidisciplinary approaches to current treatment for malignant pleural mesothelioma using surgery, chemotherapy, immunotherapy, and radiotherapy. It also sheds light on some recent studies (EMPHACIS, CALGB30901, Checkmate-743, etc.) that have led to significant developments in recent years with clinically meaningful results.
- | Darzalex (daratumumab) / J&J
Journal: Response to daratumumab-retreatment in patients with multiple myeloma. (Pubmed Central) - Sep 23, 2024
Our findings suggest that well-selected daratumumab-exposed MM patients may show rewarding responses to daratumumab retreatment, the more with alternating antimyeloma combinations, initial good response and CD38-antibody-treatment pauses, thereby proving CD38-antibody-retreatment as feasible, effective and non-toxic. Confirmatory studies are required to further validate our results.
- | Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) / Roche
Journal: Enhancing systemic anti-cancer treatment (SACT) capacity: implementing and using subcutaneous atezolizumab. (Pubmed Central) - Sep 23, 2024
Confirmatory studies are required to further validate our results. No abstract available
- | Opdivo (nivolumab) / BMS
Journal: Residue-Specific Epitope Mapping of the PD-1/Nivolumab Interaction Using X-ray Footprinting Mass Spectrometry. (Pubmed Central) - Sep 23, 2024
The N-linked glycosylation sites of PD-1 were confirmed through an LC-MS/MS-based deglycosylation analysis of asparagine deamidation. In addition, subtle changes in side-chain solvent accessibility were observed in the C'D loop region of PD-1 upon complex formation with nivolumab.
- | Darzalex (daratumumab) / J&J
Journal, Immune cell: A Novel Tetravalent Bispecific Immune Cell Engager Activates Natural Killer Cells to Kill Cancer Cells without Mediating Fratricide. (Pubmed Central) - Sep 23, 2024
Notably, our findings showed that daratumumab-induced NK fratricide was restricted to CD38-CD38 crosslinking and was not related to ADCC via CD16a-CD38 crosslinking. This study is the first in the literature to show the successful engineering of a tetravalent immune cell engager composed of tandem VHH units, which achieves high affinity and anticancer activity without mediating fratricide.
- | Blincyto (blinatumomab) / Astellas, Amgen
Journal: Functional Activity of Cytokine-Induced Killer Cells Enhanced by CAR-CD19 Modification or by Soluble Bispecific Antibody Blinatumomab. (Pubmed Central) - Sep 23, 2024
CAR-MNZ bearing the CD28-OX40-CD3? signaling modules, and CAR-BG2, designed on the Tisagenlecleucel CAR sequence (Kymriah
- | sunitinib / Generic mfg.
Journal, PD(L)-1 Biomarker, IO biomarker, Metastases: Sunitinib in Patients with Metastatic Renal Cell Carcinoma with Favorable Risk: Be Aware of PD-L1 Expression. (Pubmed Central) - Sep 23, 2024
PD-L1 expression has emerged as a negative prognostic factor in RCC, particularly in sunitinib-treated patients, where higher PD-L1 levels are linked to worse outcomes. This article discusses the potential risks associated with the use of sunitinib in PD-L1-positive patients.
- | alvocidib (DSP-2033) / Sumitomo Pharma, brivanib alaninate (BMS-582664) / BMS
Biomarker, Journal: Expression, potential biological behaviour and clinical significance of MCM3 in pancreatic adenocarcinoma: a comprehensive study integrating high throughput sequencing, CRISPR screening and in-house immunohistochemistry. (Pubmed Central) - Sep 23, 2024
MCM3 is likely to be a critical element in promoting the initiation and growth of PAAD. Flavopiridol may exert its anti-PAAD effect through the interaction between MCM3, classic CDK1 targets in the cell cycle checkpoint and p53 pathway as well as related molecules in other pathways.
- || Review, Journal: Evolving Horizons in Pediatric Leukemia: Novel Insights, Challenges, and the Journey Ahead. (Pubmed Central) - Sep 23, 2024
This review also discusses the long-term outcomes among pediatric leukemia survivors, focusing on late-onset side effects associated with treatments such as chemotherapy and bone marrow transplantation, encompassing secondary malignancies, organ dysfunction, and neurocognitive impacts. Ongoing research and clinical trials are crucial to refine these therapies, enhance their efficacy, and reduce adverse effects, ultimately improving young patients' survival and quality of life.
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen, Rituxan (rituximab) / Roche
Journal: Strategies for Diagnosing and Treating Disseminated Methicillin-Sensitive Staphylococcus aureus Infections: Insights From a Pustular Eruption. (Pubmed Central) - Sep 23, 2024
Following port removal and a four-week course of ceftriaxone, the patient's condition improved...The rare presentation of vesiculopustular eruptions secondary to MSSA emphasizes the need for prompt identification and treatment to prevent severe complications. This report contributes to the limited literature on disseminated staphylococcal infections presenting as vesiculopustular eruptions in immunocompromised individuals.
- | Venclexta (venetoclax) / Roche, AbbVie, Imbruvica (ibrutinib) / AbbVie, J&J
Journal, IO biomarker: Paraneoplastic myelitis associated with Waldenstr (Pubmed Central) - Sep 23, 2024
However, he subsequently relapsed and symptomatically worsened while on rituximab therapy...Our observation of sustained disease response in this patient may support a role for concurrent BTK and BCL2 inhibition in paraneoplastic myelitis associated with B-cell lymphoproliferative disorders. However, this observation needs to be validated in larger cohort studies and potentially in clinical trials if further data are supportive.
- | Imdelltra (tarlatamab-dlle) / Amgen
Journal: Tarlatamab for Large Cell Neuroendocrine Carcinoma in a Young Adult: A Case Report. (Pubmed Central) - Sep 23, 2024
Treatment was complicated by transient cytokine release syndrome but resulted in a partial response. Bispecific T cell engagers may offer a novel treatment approach for large cell neuroendocrine carcinoma of the lung.
- || Ibrance (palbociclib) / Pfizer
PK/PD data, Journal, Metastases: Exploring pharmacokinetic variability of palbociclib in HR+/HER2- metastatic breast cancer: a focus on age, renal function, and drug-gene interactions. (Pubmed Central) - Sep 23, 2024
Furthermore, exploring the drug-drug-gene interactions between inhibitors of CYP3A and P-glycoprotein with their respective genetic variants revealed two patient groups with statistically different percentage deviations (p = 0.0075, p = 0.0012, and p = 0.0191, respectively). These results could help address cases where pharmacokinetic covariates or subclinical conditions impair palbociclib adherence or response, aiming to offer tailored dosing strategies or monitoring for individual patients.
- || Review, Journal, PD(L)-1 Biomarker, IO biomarker: Immunotherapy for hepatocellular carcinoma. (Pubmed Central) - Sep 23, 2024
Combination therapy with either atezolizumab (anti-PD-L1) and bevacizumab (anti-VEGF) or durvalumab (anti-PD-L1) and tremelimumab (anti-CTLA-4) is now recognised as standard of care for advanced HCC...Herein, we review the current understanding of the immune landscape in which HCC develops and the evidence for ICI-based therapeutic strategies in HCC. Additionally, we describe the state of biomarker development and novel immunotherapy approaches in HCC which have progressed beyond the pre-clinical stage and into early-phase trials.
- || MEDI5083 / AstraZeneca, Imfinzi (durvalumab) / AstraZeneca
P1 data, Journal, Combination therapy, Metastases: A phase 1 study of the CD40 agonist MEDI5083 in combination with durvalumab in patients with advanced solid tumors. (Pubmed Central) - Sep 23, 2024
Additionally, we describe the state of biomarker development and novel immunotherapy approaches in HCC which have progressed beyond the pre-clinical stage and into early-phase trials. MEDI5083 maximum tolerated dose was 5
- | Kymriah (tisagenlecleucel-T) / Novartis, Yescarta (axicabtagene ciloleucel) / Gilead
Retrospective data, Journal: Comparison of the Efficacy and Safety of Axi-Cel and Tisa-Cel Based on Meta-Analysis. (Pubmed Central) - Sep 23, 2024
CAR T-cell therapy is an effective treatment option for relapsed/refractory B-cell lymphoma. Axi-cel has better ORR and survival advantages compared with tisa-cel; however, axi-cel has higher incidence rates of CRS and ICANS compared with tisa-cel.
- || mRNA-4157 / Merck (MSD), Moderna, BNT111 / BioNTech
Review, Journal: mRNA vaccines: a new era in vaccine development. (Pubmed Central) - Sep 23, 2024
Overall, mRNA cancer vaccines represent a cutting-edge therapeutic approach that holds the promise of transforming cancer treatment. As research progresses, addressing challenges and refining manufacturing processes will be crucial in advancing these vaccines from clinical trials to mainstream oncology practice, offering new hope for patients in the fight against cancer.
- | Journal, PD(L)-1 Biomarker, IO biomarker: Prognosis and immunotherapeutic implications of molecular classification of cervical cancer based on immunophenoscore-related genes. (Pubmed Central) - Sep 23, 2024
In contrast, cluster3 had higher TTN and PIK3CA mutations and greater sensitivity to AZ628, Dasatinib, Doxorubicin, HG-6-64-1, JQ12, Midostaurin, PF-562271, TAE684, and WH-4-023. In conclusion, we developed a feasible risk score model based on IPS-related genes for cervical cancer prognosis and identified potential drugs for different cervical cancer subtypes.
- ||| Venclexta (venetoclax) / Roche, AbbVie, Rituxan (rituximab) / Roche, Imbruvica (ibrutinib) / AbbVie, J&J
Trial termination: A Study of ABT-199 Plus Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (clinicaltrials.gov) - Sep 23, 2024
P1, N=10, Terminated, Sponsor: Hackensack Meridian Health
In conclusion, we developed a feasible risk score model based on IPS-related genes for cervical cancer prognosis and identified potential drugs for different cervical cancer subtypes. Active, not recruiting --> Terminated; Lack of enrollment
- || AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial: mFOLFOX7 Plus Camrelizumab and Apatinib in BCLC Stage A/B Hepatocellular Carcinoma Patients Beyond Milan Criteria (clinicaltrials.gov) - Sep 23, 2024
P2, N=29, Recruiting, Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- | bemarituzumab (AMG 552) / Amgen
Phase classification: FORTITUDE-103: A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer. (clinicaltrials.gov) - Sep 23, 2024
P1/2, N=80, Recruiting, Sponsor: Amgen
Active, not recruiting --> Terminated; Lack of enrollment Phase classification: P1 --> P1/2
- || oleclumab (MEDI9447) / AstraZeneca, Imfinzi (durvalumab) / AstraZeneca
New P2 trial: A Study to Investigate the Effects of Durvalumab With Oleclumab Following Chemoradiation in Participants With Locally Advanced Unresectable Non-Small Cell Lung Cancer (LADOGA) (clinicaltrials.gov) - Sep 23, 2024
P2, N=30, Not yet recruiting, Sponsor: AstraZeneca
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial completion date, Trial termination: Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery (clinicaltrials.gov) - Sep 23, 2024
P1, N=95, Terminated, Sponsor: National Cancer Institute (NCI)
Phase classification: P1 --> P1/2 Trial completion date: Sep 2025 --> Aug 2024 | Active, not recruiting --> Terminated; Inadequate accrual rate
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment closed, Trial completion date, Trial primary completion date: CA209-324: An Open-Label Phase II Study of Nivolumab or Nivolumab/Ipilimumab in Adult Participants With Progessive/ Recurrent Meningioma (clinicaltrials.gov) - Sep 23, 2024
P2, N=40, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Trial completion date: Sep 2025 --> Aug 2024 | Active, not recruiting --> Terminated; Inadequate accrual rate Recruiting --> Active, not recruiting | Trial completion date: Sep 2025 --> Dec 2025 | Trial primary completion date: Mar 2025 --> Dec 2024
- || Keytruda (pembrolizumab) / Merck (MSD)
Trial completion, Trial completion date, Trial primary completion date: Assess the Efficacy of Pembrolizumab Plus Radiotherapy or Ablation in Metastatic Colorectal Cancer Patients (clinicaltrials.gov) - Sep 23, 2024
P2, N=34, Completed, Sponsor: Memorial Sloan Kettering Cancer Center
Recruiting --> Active, not recruiting | Trial completion date: Sep 2025 --> Dec 2025 | Trial primary completion date: Mar 2025 --> Dec 2024 Active, not recruiting --> Completed | Trial completion date: Apr 2025 --> Sep 2024 | Trial primary completion date: Apr 2025 --> Sep 2024
- | Keytruda (pembrolizumab) / Merck (MSD)
Trial completion date: A Phase II Study of the Combination of Pembrolizumab and ATRA Combination Treatment of Relapsed HL and B-NHL (clinicaltrials.gov) - Sep 23, 2024
P2, N=24, Recruiting, Sponsor: Rita Assi
Active, not recruiting --> Completed | Trial completion date: Apr 2025 --> Sep 2024 | Trial primary completion date: Apr 2025 --> Sep 2024 Trial completion date: Dec 2030 --> Sep 2029
- |||||| Keytruda (pembrolizumab) / Merck (MSD)
New trial: CARE Initiative: Real-world Emulation of the KEYNOTE-189 Trial [DS3] (clinicaltrials.gov) - Sep 23, 2024
P=N/A, N=851, Completed, Sponsor: Aetion, Inc.
- | Blincyto (blinatumomab) / Astellas, Amgen
New P2/3 trial: BBClean: Efficacy Study of Blinatumomab Clean Up Early Residual Disease for Newly Diagnosed Pediatric B Lymphoblastic Leukemia (clinicaltrials.gov) - Sep 23, 2024
P2/3, N=90, Recruiting, Sponsor: Shanghai Jiao Tong University School of Medicine
- | Tyvyt (sintilimab) / Eli Lilly
New P2 trial: A Single-center, Single-arm Phase II Clinical Study Based on FAPI-PET/CT Technology to Predict Pathological Complete Response After Neoadjuvant Chemoradiotherapy for MSS Rectal Cancer (clinicaltrials.gov) - Sep 23, 2024
P2, N=43, Not yet recruiting, Sponsor: Sun Yat-sen University
- ||| AOC-1044 / Eli Lilly
Enrollment status, Enrollment change: EXPLORE44OLE: Ph2 Open-label Study of AOC 1044 in Duchenne Muscular Dystrophy Participants with Mutations Amenable to Exon44 Skipping (clinicaltrials.gov) - Sep 23, 2024
P2, N=35, Recruiting, Sponsor: Avidity Biosciences, Inc.
Trial completion date: Dec 2030 --> Sep 2029 Enrolling by invitation --> Recruiting | N=24 --> 35
- | Tecentriq (atezolizumab) / Roche
Journal, Gene Signature, PD(L)-1 Biomarker, IO biomarker: The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer. (Pubmed Central) - Sep 23, 2024
We also assessed the predictive function of the immuno-oncology (IO) score in expression data of patients treated with pembrolizumab plus paclitaxel (N = 29) or CT alone (N = 56) in the I-SPY2 trial...In IO-negative cancers, pCR rates were 46.7% versus 16.1%. DetermaIO identified patients who benefited from neoadjuvant immunotherapy resulting in improved pCR rate, independently of PDL1.
- | Rituxan (rituximab) / Roche, Calquence (acalabrutinib) / AstraZeneca
Journal, Combination therapy: Acalabrutinib alone or in combination with rituximab for follicular lymphoma: An open-label study. (Pubmed Central) - Sep 23, 2024
Acalabrutinib monotherapy was also well tolerated and active in R/R FL. These results support further study of acalabrutinib alone and in combination with rituximab in FL.
- | SAR442257 / Sanofi
Journal, IO biomarker, Trispecific: A CD38/CD3xCD28 trispecific T-cell engager as a potentially active agent in multiple myeloma patients relapsed and/or refractory to anti-CD38 monoclonal antibodies. (Pubmed Central) - Sep 23, 2024
While complete CD38 loss is not observed upon relapses after treatment with anti-CD38 monoclonal antibodies (mAb), there is downregulation of surface CD38 expression and decreased number and function of NK cells, which renders these patients resistant to retreatment with anti-CD38 mAb. Here, we provide preclinical evidence that RRMM patients previously exposed to anti-CD38 mAb could benefit from T-cell-based immunotherapy that depend less on CD38 antigen density and NK-cell activity, such as the novel CD38/CD3xCD28 trispecific T-cell engager, SAR442257.
- | Orencia (abatacept) / BMS, Rituxan (rituximab) / Roche
Journal: Effectiveness of janus kinase inhibitors compared with biologic disease modifying anti-rheumatic drugs on pain reduction in rheumatoid arthritis: Results from a nationwide Swedish cohort study. (Pubmed Central) - Sep 23, 2024
JAKis had a slightly better effect on pain outcomes at 3 and 12 months compared with TNFis, with significantly greater differences in patients previously treated with ?2 bDMARDs. The effect of JAKis on pain reduction was at least similar to that of non-TNFi bDMARDs.
- | Xtandi (enzalutamide capsule) / Pfizer, Astellas, Keytruda (pembrolizumab) / Merck (MSD)
Journal, Metastases: Bipolar androgen therapy for treatment of metastatic castration-resistant prostate cancer: A case series. (Pubmed Central) - Sep 23, 2024
Despite eventual progression in some cases, BAT offers a period of disease control. Further research is needed to optimize patient selection and understand the molecular determinants of BAT responsiveness.
- | Imfinzi (durvalumab) / AstraZeneca
Retrospective data, Journal: The role of radiotherapy in extensive-stage small cell lung cancer after durvalumab-based immunochemotherapy: A retrospective study. (Pubmed Central) - Sep 23, 2024
Further research is needed to optimize patient selection and understand the molecular determinants of BAT responsiveness. Addition of RT after first-line immunochemotherapy significantly improved survival outcomes with manageable toxicity in ES-SCLC.
- | Opdivo (nivolumab) / BMS
New trial: IMNR: Inflammatory Markers (ICC, MCVL) and Nivolumab Response: Predicting Immunotherapy Success in Metastatic RCC (clinicaltrials.gov) - Sep 23, 2024
P=N/A, N=99, Completed, Sponsor: Dr. Lutfi Kirdar Kartal Training and Research Hospital
- || Yuanruida (inaticabtagene autoleucel) / CASI
New P2 trial: Combination of Inaticabtagene Autoleucel With Autologous Hematopoietic Stem Cell Transplantation for Adolescents or Adults With MRD-Positive B-Cell Acute Lymphoblastic Leukemia in Initial Complete Remission. (clinicaltrials.gov) - Sep 23, 2024
P2, N=20, Recruiting, Sponsor: Institute of Hematology & Blood Diseases Hospital, China
- ||| LY-4066434 / Eli Lilly
New P1 trial: A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors (clinicaltrials.gov) - Sep 23, 2024
P1, N=750, Not yet recruiting, Sponsor: Eli Lilly and Company
- ||| Yutuo (zimberelimab) / Arcus Biosci, Gilead, quemliclustat (AB680) / Arcus Biosci, Gilead
Enrollment open: Zimberelimab and Quemliclustat in Combination with Chemotherapy for the Treatment of Patients with Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma (clinicaltrials.gov) - Sep 23, 2024
P1/2, N=56, Recruiting, Sponsor: Jonsson Comprehensive Cancer Center
Addition of RT after first-line immunochemotherapy significantly improved survival outcomes with manageable toxicity in ES-SCLC. Suspended --> Recruiting
- | TG01 vaccine / Circio Holding, balstilimab (AGEN2034) / Agenus
Enrollment closed: TESLA: Tg01 Vaccine / Qs-21 Stimulon (clinicaltrials.gov) - Sep 23, 2024
P2, N=24, Active, not recruiting, Sponsor: University of Kansas Medical Center
Suspended --> Recruiting Recruiting --> Active, not recruiting
- |||| Tevimbra (tislelizumab-jsgr) / BeiGene, ociperlimab (BGB-A1217) / BeiGene
Trial completion: AdvanTIG-205: Ociperlimab with Tislelizumab and Chemotherapy in Participants with Untreated Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov) - Sep 23, 2024
P2, N=272, Completed, Sponsor: BeiGene
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | AiTan (rivoceranib) / HLB Bio Group
New P1/2 trial: Safety and Efficacy of Cryoablation With Karelizumab and Apatinib for Multiple Lung Cancers (clinicaltrials.gov) - Sep 23, 2024
P1/2, N=20, Not yet recruiting, Sponsor: Zhou Chengzhi
- || JANX007 / Janux Therapeutics
Trial completion date, Trial primary completion date, Metastases: Study of JANX007 in Subjects with Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01) (clinicaltrials.gov) - Sep 23, 2024
P1, N=105, Recruiting, Sponsor: Janux Therapeutics
Active, not recruiting --> Completed Trial completion date: Mar 2025 --> Dec 2026 | Trial primary completion date: Aug 2024 --> Jul 2025
- | Venclexta (venetoclax) / Roche, AbbVie, Gazyva (obinutuzumab) / Roche, Biogen, Calquence (acalabrutinib) / AstraZeneca
Trial completion date, Trial primary completion date, Combination therapy: Acalabrutinib in Combination with Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Sep 23, 2024
P2, N=52, Recruiting, Sponsor: Ohio State University Comprehensive Cancer Center
Trial completion date: Mar 2025 --> Dec 2026 | Trial primary completion date: Aug 2024 --> Jul 2025 Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025